Vaccinex is a biotechnology business based in the US. Vaccinex shares (VCNX) are listed on the NASDAQ and all prices are listed in US Dollars. Vaccinex employs 37 staff and has a trailing 12-month revenue of around $356,000.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $5.63 |
|---|---|
| 52-week range | $4.21 - $51.98 |
| 50-day moving average | $5.98 |
| 200-day moving average | $7.48 |
| Wall St. target price | $7.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-3.96 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.63 from 2024-09-06
| 1 week (2024-08-30) | -1.75% |
|---|---|
| 1 month (2024-08-07) | 17.29% |
| 3 months (2024-06-07) | -24.23% |
| 6 months (2024-03-07) | -32.09% |
| 1 year (2023-09-07) | 2,408.91% |
|---|---|
| 2 years (2022-09-07) | 640.79% |
| 3 years (2021-09-07) | 140.60% |
| 5 years (2019-09-06) | 5.971 |
| Revenue TTM | $356,000 |
|---|---|
| Gross profit TTM | $-13,704,000 |
| Return on assets TTM | -495.64% |
| Return on equity TTM | -759.09% |
| Profit margin | 0% |
| Book value | $-2.68 |
| Market Capitalization | $9.9 million |
TTM: trailing 12 months
We're not expecting Vaccinex to pay a dividend over the next 12 months.
Vaccinex's shares were split on a 1:14 basis on 19 February 2024. So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Vaccinex shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for Vaccinex shares which in turn could have impacted Vaccinex's share price.
Over the last 12 months, Vaccinex's shares have ranged in value from as little as $4.21 up to $51.975. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vaccinex's is 0.916. This would suggest that Vaccinex's shares are less volatile than average (for this exchange).
Vaccinex, Inc. , a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S. A.
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.